0JQ2 Stock Overview
A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
KALA BIO, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$6.84 |
52 Week High | US$9.00 |
52 Week Low | US$4.47 |
Beta | -2.13 |
11 Month Change | 26.67% |
3 Month Change | 9.44% |
1 Year Change | -1.58% |
33 Year Change | -93.49% |
5 Year Change | n/a |
Change since IPO | -99.09% |
Recent News & Updates
Recent updates
Shareholder Returns
0JQ2 | GB Biotechs | GB Market | |
---|---|---|---|
7D | -3.0% | -0.3% | -1.3% |
1Y | -1.6% | -14.6% | 8.9% |
Return vs Industry: 0JQ2 exceeded the UK Biotechs industry which returned -14.6% over the past year.
Return vs Market: 0JQ2 underperformed the UK Market which returned 8.9% over the past year.
Price Volatility
0JQ2 volatility | |
---|---|
0JQ2 Average Weekly Movement | 10.3% |
Biotechs Industry Average Movement | 8.3% |
Market Average Movement | 4.7% |
10% most volatile stocks in GB Market | 9.5% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0JQ2's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0JQ2's weekly volatility has decreased from 16% to 10% over the past year, but is still higher than 75% of UK stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 43 | Mark Iwicki | www.kalarx.com |
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company’s product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases.
KALA BIO, Inc. Fundamentals Summary
0JQ2 fundamental statistics | |
---|---|
Market cap | US$32.21m |
Earnings (TTM) | -US$38.72m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs 0JQ2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0JQ2 income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$38.72m |
Earnings | -US$38.72m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -8.40 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 253.8% |
How did 0JQ2 perform over the long term?
See historical performance and comparison